INTS
Intensity Therapeutics, Inc. (INTS) Economic Moat Analysis (2026)
No material changes this month.
Intangible Assets
No filing evidence provided of patents, proprietary software, regulatory approvals, or brand assets that would let INTS charge meaningfully better prices than peers over 5–10 years.
The available FMP data show deeply negative ROIC and ROCE, which is inconsistent with durable intangible-led pricing power versus peers.
With no disclosed customer lock-in or proprietary IP evidence, any intangible advantage appears limited and readily replicable relative to stronger peers.
Switching Costs
No filing evidence provided of contractual lock-in, embedded workflows, or mission-critical integration that would make customers costly to replace INTS versus peers.
The negative profitability profile suggests customers are not paying a premium that would indicate strong retention economics or switching friction.
Absent evidence of multi-year contracts, data migration burden, or ecosystem dependence, switching costs appear materially weaker than in peer businesses with sticky enterprise relationships.
Network Effects
No evidence was provided that INTS operates a platform where more users, developers, or counterparties directly increase value for other users.
The business metrics do not indicate self-reinforcing adoption or margin expansion that would typically accompany network effects versus peers.
Without ecosystem scale or two-sided participation data, network effects cannot be credited as a durable moat driver.
Cost Advantage
The reported negative ROIC and ROCE indicate INTS is not converting capital into returns better than peers, which argues against a structural cost advantage.
No evidence was provided of superior scale purchasing, manufacturing efficiency, or lower unit economics that would sustain pricing power.
In the absence of demonstrable cost leadership, peers with better operating leverage would likely defend share more effectively.
Efficient Scale
No evidence was provided that INTS serves a niche market where one or two firms can profitably dominate and deter entry.
The available metrics do not show the kind of high-return, capacity-constrained economics that usually support efficient-scale protection versus peers.
Without proof of regulated scarcity, local monopoly dynamics, or high fixed-cost barriers, efficient scale appears absent.
Overall Score
INTS shows no evidenced structural moat in the provided materials, and the negative ROIC/ROCE profile points to weak pricing power and limited retention versus peers; on the available evidence, the business appears readily replicable rather than durably advantaged.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Intensity Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
